1 |
Identification of Novel Molecular Targets of Resveratrol in Colorectal CarcinogenesisWhitlock, Nichelle Chantil 01 December 2011 (has links)
Current research suggests resveratrol, a phytoalexin found predominately in grapes, may function as a chemopreventive and/or chemotherapeutic agent for various cancers, including colorectal cancer. However, the underlying mechanism(s) involved in these activities remain elusive. Thus, the objective of the studies discussed here sought to investigate the effect of resveratrol treatment on gene modulation in human colorectal cancer cells in order to identify and characterize novel molecular targets that contribute to the observed anticancer activities of resveratrol. Here, we identify activating transcription factor 3 (ATF3) and early growth response-1 (Egr-1) as novel targets of resveratrol and provide data to elucidate the mechanism(s) of regulation and how each target contributes to the anticancer effect of resveratrol in colorectal cancer cells. We demonstrate the involvement of resveratrol in ATF3 transcriptional regulation, which is facilitated by Egr-1 and Krüppel-like factor 4 interactions, and show that ATF3 contributes, at least partially, to resveratrol-induced apoptosis (Chapter 3). Moreover, we suggest that increased Egr-1 transcriptional activity by resveratrol requires posttranslational acetylation of Egr-1 in a SIRT1-independent manner. This acetylation by resveratrol may contribute to Egr-1-mediated expression of the pro-apoptotic protein nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) induced by the phytoalexin (Chapter 4). Taken together, the work presented here provide (1) novel mechanisms by which resveratrol induces ATF3 and Egr-1 expression and (2) represent additional explanations for the anti-tumorigenic/anti-carcinogenic effects of resveratrol in human colorectal cancer cells.
|
2 |
Régulation de l'expression de PPARγ dans l'arthroseNebbaki, Salwa Sarah 06 1900 (has links)
L’arthrose (OA) est une maladie dégénérative très répondue touchant les articulations. Elle est caractérisée par la destruction progressive du cartilage articulaire, l’inflammation de la membrane synoviale et le remodelage de l’os sous chondral. L’étiologie de cette maladie n’est pas encore bien définie. Plusieurs études ont été menées pour élucider les mécanismes moléculaires et cellulaires impliqués dans le développement de l’OA.
Les effets protecteurs du récepteur activé par les proliférateurs de peroxysomes gamma (PPARγ) dans l'OA sont bien documentés. Il a été démontré que PPARγ possède des propriétés anti-inflammatoires et anti-cataboliques. Aussi, plusieurs stimuli ont été impliqués dans la régulation de l’expression de PPARγ dans différents types cellulaires. Cependant, les mécanismes exacts responsables de cette régulation ainsi que le profil de l’expression de ce récepteur au cours de la progression de l’OA ne sont pas bien connus.
Dans la première partie de nos travaux, nous avons essayé d’élucider les mécanismes impliqués dans l’altération de l’expression de PPARγ dans cette maladie. Nos résultats ont confirmé l’implication de l’interleukine-1β (IL-1β), une cytokine pro-inflammatoire, dans la réduction de l’expression de PPARγ au niveau des chondrocytes du cartilage articulaire. Cet effet coïncide avec l'induction de l’expression du facteur de transcription à réponse précoce de type 1 (Egr-1). En plus, la diminution de l'expression de PPARγ a été associée au recrutement d'Egr-1 et la réduction concomitante de la liaison de Sp1 au niveau du promoteur de PPARγ.
Dans la deuxième partie de nos travaux, nous avons évalué le profil d’expression de ce récepteur dans le cartilage au cours de la progression de cette maladie. Le cochon d’inde avec OA spontanée et le chien avec OA induite par rupture du ligament croisé antérieur (ACLT) deux modèles animaux d’OA ont été utilisés pour suivre l’expression des trois isoformes de PPARs : PPAR alpha (α), PPAR béta (β) et PPAR gamma (γ) ainsi que la prostaglandine D synthase hématopoïétique (H-PGDS) et la prostaglandine D synthase de type lipocaline (L-PGDS) deux enzymes impliquées dans la production de l’agoniste naturel de PPARγ, la 15-Deoxy-delta(12,14)-prostaglandine J(2) (15d-PGJ2).
Nos résultats ont démontré des changements dans l’expression de PPARγ et la L-PGDS. En revanche, l’expression de PPARα, PPARβ et H-PGDS est restée stable au fil du temps. La diminution de l’expression de PPARγ dans le cartilage articulaire semble contribuer au développement de l’OA dans les deux modèles animaux. En effet, le traitement des chondrocytes par de siRNA dirigé contre PPARγ a favorisé la production des médiateurs arthrosiques tels que l'oxyde nitrique (NO) et la métalloprotéase matricielle de type 13 (MMP-13), confirmant ainsi le rôle anti-arthrosique de ce récepteur. Contrairement à ce dernier, le niveau d'expression de la L-PGDS a augmenté au cours de la progression de cette maladie. La surexpression de la L-PGDS au niveau des chondrocytes humains a été associée à la diminution de la production de ces médiateurs arthrosiques, suggérant son implication dans un processus de tentative de réparation.
En conclusion, l’ensemble de nos résultats suggèrent que la modulation du niveau d’expression de PPARγ, de la L-PGDS et d’Egr-1 au niveau du cartilage articulaire pourrait constituer une voie thérapeutique potentielle dans le traitement de l’OA et probablement d’autres formes d'arthrite. / Osteoarthritis (OA) is the most common degenerative joint disease. It is characterised by progressive destruction of articular cartilage, synovial inflammation and subchondral bone remodelling. The complete etiology of OA is still not well defined. Several studies have been carried out to elucidate the molecular and cellular mechanisms involved in OA development.
The protective effects of Peroxisome proliferator-activated receptor gamma (PPARγ) in OA have been well documented. It has been demonstrated that PPARγ exhibit anti-inflammatory and anti-catabolic properties. Although many stimuli have been reported to regulate the expression of PPARγ in several cell types. However, little information is available on the exact mechanisms that govern its regulation as well as the expression profile of this recepteur during the course of the disease.
In the first part of this work, we tried to elucidate the mechanisms involved in the alteration of PPARγ expression in OA. Our findings confirm that interleukin-1 beta (IL-1β), a proinflammatory cytokine, down regulate the expression of PPARγ in articular chondrocytes. This effect coincided with the induction of early growth response protein-1 (Egr-1) expression. In addition, down regulation of PPARγ expression was associated with Egr-1 recruitment to and concomitant reduction in Sp1 occupancy at PPARγ promoter.
In the second part of this work, we evaluated the expression profile of this receptor in cartilage during the progression of OA. Spontaneous Hartley guinea pig model and anterior cruciate ligament transection (ACLT) dog model were used to follow the expression of three isoforms of PPARs: PPAR alpha (α), PPAR beta (β) and PPAR gamma (γ) as well as hematopoietic prostaglandin D synthase (H-PGDS) and lipocalin-type prostaglandin D synthase (L-PGDS) two enzymes involved in the production of the natural agonist PAARγ, 15-Deoxy-delta(12,14)-prostaglandin J(2) (15d PGJ2).
Our reultats showed changes in the expression of PPARγ and L-PGDS. In contrast, the level of PPARα, PPARβ and H-PGDS was constant over time. The decrease in PPARγ levels in articular chondrocytes suggest that it may be a contributing factor in OA development in both animal models used in this study. Furthermore, siRNA silencing of PPARγ resulted in an enhanced production of osteoarthric mediators such as matrix metalloproteinase-13 (MMP-13) and nitric oxide (NO). Thus, confirming the anti-arthritic role of this receptor. In contrast, unlike the later, there was an increase in the expression level of L-PGDS during disease progression. The overexpression of L-PGDS in human chondrocytes was associated with reduced production of these osteoarthric mediators, suggesting its involvement in repair process.
In summary, our data suggest that the modulation of PPARγ, L-PGDS and Egr-1 expression levels in articular cartilage may be a potential therapeutic approach in the treatment of OA and probably other forms of arthritis.
|
3 |
The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies / Le rôle d'EGR-1 et du flux calcique dans l'activité antitumorale des anticorps monoclonaux anti-CD20Spasevska, Ivana 01 December 2017 (has links)
Les anticorps monoclonaux (AcM) anti-CD20 sont essentiels pour le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique (LLC). Les AcM agissent soit en activant directement la signalisation apoptotique dans les cellules cibles, soit via le système immunitaire. Dans une étude préclinique, nous avons montré que le traitement avec AcM anti-CD20, rituximab et GA101, induit l'expression de la protéine early growth response 1 (EGR-1) (Dalle et al., 2011). EGR-1 est un facteur de transcription régulé par le calcium (Ca2+) et CD20 est impliqué dans la régulation du flux calcique transmembranaire. Nous avons donc étudié le rôle d'EGR-1 et du flux Ca2+ dans l'activité cytotoxique des AcM anti-CD20. Nous avons montré qu'EGR-1 est rapidement induit suite à l'exposition au rituximab et à GA101. La baisse de l'expression d'EGR-1 par shRNA a supprimé l'effet cytotoxique du GA101 à la fois in vitro et in vivo, indiquant qu'EGR-1 est requis pour la mort cellulaire médiée par CD20. De plus, la surexpression d'EGR-1 augmente la sensibilité au GA101 in vitro et in vivo. En outre, nos résultats indiquent que les AcM anti-CD20 induisent un flux Ca2+. Le blocage du flux Ca2+ par inhibiteurs de canaux calciques (ICC) a aboli l'induction d'EGR-1 ainsi que l'efficacité du GA101 in vivo et ex vivo dans des échantillons de LLC. Plus important, nos données indiquent que les patients recevant des ICC ont une moins bonne réponse au traitement par les AcM anti-CD20. En conclusion, nous avons identifié EGR-1 comme potentiel biomarqueur pour prédire la réponse à la thérapie anti-CD20 et démontré que les ICC ont un impact négatif sur l'efficacité des AcM anti-CD20 chez les patients / Anti-CD20 monoclonal antibodies (mAbs) are an essential component of the treatment of patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). They mediate their antitumor effects by activating the immune system or by direct apoptotic signaling in target cells. In a previous preclinical study, we showed that treatment with anti-CD20 mAbs, rituximab and GA101, resulted in upregulated expression of early growth factor 1 (EGR-1) (Dalle et al. 2011). EGR-1 is a calcium (Ca2+) regulated transcription factor and CD20 is hypothesized to regulate transmembrane Ca2+ flux. Therefore, we aimed to assess the role of EGR-1 and Ca2+ flux in the cytotoxic activity of anti-CD20 mAbs. We have shown that EGR-1 expression is rapidly upregulated in CD20+ cells following rituximab and GA101 exposure. Decreasing EGR-1 expression by shRNA abolishes the direct cytotoxic effect of GA101 both in vitro and in vivo, indicating that EGR-1 is required for CD20-mediated cell death. Additionally, the overexpression of EGR-1 enhances the cytotoxic activity of GA101 both in vitro and in vivo. Furthermore, our results indicate that anti-CD20 mAbs induce calcium influx. Blocking the Ca2+ flux with calcium channel blockers (CCB) abolishes EGR-1 induction and impaires the GA101 efficacy in vivo and ex vivo in CLL blood samples. More importantly, our data indicate that patients receiving CCBs and anti-CD20 therapy have worst progression free survival and overall survival. In conclusion we have identified EGR-1 as a potential biomarker to predict response to anti-CD20 therapy. We demonstrated that co-treatement with CCBs negatively impacts the outcome of patients receiving anti-CD20 mAbs
|
4 |
Expression de l’early growth response protein-1 (Egr-1) par le peroxyde d’hydrogène (H2O2) nécessite l’activation de l’IGF-1R, de c-Src et de PKC dans les CMLVRondeau, Vincent 12 1900 (has links)
Une augmentation de la génération des dérivés réactifs de l’oxygène (DRO), tels que le peroxyde d’hydrogène (H2O2), joue un rôle clé dans la pathophysiologie des maladies cardiovasculaires (MCV). La croissance et la prolifération excessives des cellules musculaires lisses vasculaires (CMLV) ont été suggérées comme étant les mécanismes à la base de la dysfonction vasculaire. Une implication potentielle du facteur de transcription Early growth response protein-1 (Egr-1) dans le développement des dommages vasculaires a été proposée. Des études ont démontré que le H2O2 augmente l’expression de l’Egr-1 dans les CMLV. Cependant, les voies de signalisation intracellulaire menant à l’expression de l’Egr-1 en réponse au H2O2 restent à établir. L’objectif de cette étude vise à examiner les différentes voies de signalisation impliquées dans l’expression de l’Egr-1 induite par le H2O2 dans les CMLV. Le H2O2 augmente l’expression de l’Egr-1 en fonction du temps et de la dose dans les CMLV A10. Le blocage pharmacologique des tyrosines kinases insulin-like growth factor-1 receptor (IGF-1R) et c-Src, par AG1024 et PP2 respectivement, atténue l’expression de l’Egr-1 induite par le H2O2, alors que l’AG1478, un inhibiteur de l’epidermal growth factor receptor (EGFR), et le PP3, l’analogue inactif du PP2, n’ont aucun effet sur l’expression de l’Egr-1. Le blocage pharmacologique de l’extracellular signal-regulated kinase 1/2 (ERK1/2), par UO126, et de la protéine kinase C (PKC), par rottlerin et rö-31-8220, diminue l’expression de l’Egr-1 induite par le H2O2. En résumé, nos résultats suggèrent que le H2O2 déclenche l’expression de l’Egr-1 via l’IGF-1R, la kinase c-Src, l’ERK1/2 et la PKC dans les CMLV. / Increased generation of reactive oxygen species (ROS), such as hydrogen peroxide (H2O2), plays a key role in the pathophysiology of cardiovascular diseases (CVD). Excessive growth and proliferation of vascular smooth muscle cells (VSMCs) has been suggested as an important contributor of vascular dysfunction. A potential involvement of early growth response protein-1 (Egr-1), a zinc-finger transcription factor, in the development of vascular injury has been proposed. Recent studies have shown that H2O2 increases Egr-1 expression in VSMCs. However, signaling events leading to H2O2-induced Egr-1 expression are not fully understood. Therefore, this study aims to examine the signaling pathways implicated in H2O2-induced Egr-1 expression in VSMC. H2O2 increased Egr-1 expression in a time and dose-dependent fashion in A10 VSMC. Pharmacological blockade of tyrosine kinases insulin-like growth factor-1 receptor (IGF-1R) and c-Src, by AG1024 and PP2 respectively, attenuated H2O2-induced Egr-1 expression, while AG1478, an epidermal growth factor receptor (EGFR) inhibitor, and PP3, the inactive analogue of PP2, have no effect on Egr-1 expression. Pharmacological blockade of extracellular signal-regulated kinase 1/2 (ERK1/2), by UO126, and proteine kinase C (PKC), by rottlerin and rö-31-8220, decreased H2O2-induced Egr-1 expression. In summary, our results suggest that H2O2 triggers Egr-1 expression through IGF-1R, c-Src, ERK1/2 and PKC in VSMC.
|
5 |
Effet de l'activation de PPARy sur l'expression de la mPGES-1 et rôle des polymorphismes de PPARy dans l'arthroseCheng, Saranette January 2005 (has links)
Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.
|
6 |
Retrograde signalling within fear neurocircuitry: Nitric oxide signalling from the lateral nucleus of the amygdala regulates thalamic EGR-1 mediated alterations of presynaptic protein levels during auditory fear conditioningOvereem, Kathie January 2009 (has links)
Previous research has shown that nitric oxide signalling in the lateral nucleus of the amygdala is required for the consolidation of Pavlovian conditioned fear. Given the evidence that nitric oxide can act as a retrograde signalling molecule in in vitro models of memory consolidation the question arises whether this is also occurring within behavioural memory models? Using auditory fear conditioning this research shows that nitric oxide does indeed act as retrograde signalling molecule in the fear system. Its synthesis in the lateral nucleus of the amygdala regulates conditioning induced expression of the immediate early gene early growth response gene 1 (EGR-1) in cells of the auditory thalamus that project to the lateral nucleus of the amygdala. The regulation of EGR-1 expression by the lateral nucleus of the amygdala was proven to be dependent on amygdala-based cellular excitation, nitric oxide synthesis and NR2B-NMDA receptor activation but not ERK/MAPK activity. Using an EGR-1 antisense oligonucleotide to prevent training induced EGR-1 expressions in the auditory thalamus it was shown that this gene upregulation is necessary for the consolidation of conditioned fear. Finally, inhibition of EGR-1 upregulation in the auditory thalamus was proven to impair conditioning induced increases in the presynaptic proteins synaptophysin, and synapsin II and II back in the lateral nucleus of the amygdala. Overall, the results of this dissertation have shown that nitric oxide acts as a retrograde messenger in a mammalian memory system by modulating gene expression in presynaptic cells. This modulation of gene expression serves to increase levels of presynaptic proteins back at the origin of nitric oxide synthesis. This supports the long standing doctrine that nitric oxide acts as a retrograde signalling molecule to coordinate presynaptic changes associated with memory formation.
|
7 |
Retrograde signalling within fear neurocircuitry: Nitric oxide signalling from the lateral nucleus of the amygdala regulates thalamic EGR-1 mediated alterations of presynaptic protein levels during auditory fear conditioningOvereem, Kathie January 2009 (has links)
Previous research has shown that nitric oxide signalling in the lateral nucleus of the amygdala is required for the consolidation of Pavlovian conditioned fear. Given the evidence that nitric oxide can act as a retrograde signalling molecule in in vitro models of memory consolidation the question arises whether this is also occurring within behavioural memory models? Using auditory fear conditioning this research shows that nitric oxide does indeed act as retrograde signalling molecule in the fear system. Its synthesis in the lateral nucleus of the amygdala regulates conditioning induced expression of the immediate early gene early growth response gene 1 (EGR-1) in cells of the auditory thalamus that project to the lateral nucleus of the amygdala. The regulation of EGR-1 expression by the lateral nucleus of the amygdala was proven to be dependent on amygdala-based cellular excitation, nitric oxide synthesis and NR2B-NMDA receptor activation but not ERK/MAPK activity. Using an EGR-1 antisense oligonucleotide to prevent training induced EGR-1 expressions in the auditory thalamus it was shown that this gene upregulation is necessary for the consolidation of conditioned fear. Finally, inhibition of EGR-1 upregulation in the auditory thalamus was proven to impair conditioning induced increases in the presynaptic proteins synaptophysin, and synapsin II and II back in the lateral nucleus of the amygdala. Overall, the results of this dissertation have shown that nitric oxide acts as a retrograde messenger in a mammalian memory system by modulating gene expression in presynaptic cells. This modulation of gene expression serves to increase levels of presynaptic proteins back at the origin of nitric oxide synthesis. This supports the long standing doctrine that nitric oxide acts as a retrograde signalling molecule to coordinate presynaptic changes associated with memory formation.
|
8 |
PKR DEPENDENT UPREGULATION OF IMMEDIATE EARLY GENES AND ANTI-INFLAMMATORY CYTOKINE IL-10Chakrabarti, Arindam 01 May 2007 (has links)
No description available.
|
9 |
Role of the EGFR Pathway in Lung Remodeling and DiseaseKramer, Elizabeth L. January 2009 (has links)
No description available.
|
10 |
GADD45a-Targeted Suicide Gene Therapy for the Prevention or Treatment of Non-Small Cell Lung CarcinomaShi, Qiwen 13 July 2015 (has links)
No description available.
|
Page generated in 0.025 seconds